The use of Permacol® injections for the treatment of faecal incontinence
The aim of this study is to assess the safety and efficacy of Permacol ® implant for the treatment of idiopathic faecal incontinence using a novel injection technique. Patients with idiopathic passive faecal incontinence were selected for trans-submucosal injection of Permacol ® after assessment by...
Saved in:
Published in | Updates in surgery Vol. 64; no. 4; pp. 289 - 295 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Milan
Springer Milan
01.12.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The aim of this study is to assess the safety and efficacy of Permacol
®
implant for the treatment of idiopathic faecal incontinence using a novel injection technique. Patients with idiopathic passive faecal incontinence were selected for trans-submucosal injection of Permacol
®
after assessment by anorectal physiology and endoanal ultrasonography. Clinical assessment and St. Mark’s Incontinence Score were used to evaluate efficacy before and at two time points (1 and 2 years) after treatment. Rockwood Score were also used to determine quality of life before and after treatment. The Friedman and Chi-square tests were used to compare continuous and categorical data, respectively. A
p
value of <0.05 was deemed significant. Thirty-eight patients (24 female), median age 66 years, were recruited. At maximum clinical follow-up (median of 9 months), response to Permacol
®
injections was categorised as excellent, good, fair and poor in 12, 5, 4 and 17 patients, respectively. St. Mark’s Score improved in 72 and 63 % of patients at 1 and 2 years, respectively. However, a smaller proportion of patients (39 and 27 %, respectively) achieved a 50 %, or more, improvement in Mark’s Score. All four domains of Rockwood Quality of Life Score improved on first and second year follow-up, however, only two domains, coping and embarrassment, were statistically significant. Permacol
®
injection improved symptoms by >50 % in 39 and 27 % of patients on short and medium-term follow-ups, respectively. The trans-submucosal technique for injection of Permacol
®
in this study was safe with no significant adverse outcomes. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2038-131X 2038-3312 |
DOI: | 10.1007/s13304-012-0176-x |